Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study. (PubMed, Ann Hematol) - Jul 2, 2026 - "Combining rabbit anti-thymocyte globulin (ATG) with post-transplant cyclophosphamide (PTCy) reduces graft-versus-host disease (GVHD) after haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) but may increase cytomegalovirus (CMV) reactivation due to intensified immunosuppression...All patients received busulfan/cyclophosphamide conditioning, PTCy (40 mg/kg on days + 3 and + 4), and cyclosporine. Letermovir was not used...Given the non-randomized design, historical control, and limited sample size, no conclusions regarding efficacy preservation or superiority can be drawn. Confirmation in larger, prospective, ideally randomized studies incorporating immune monitoring is warranted."
Journal • Acute Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation
|
|
Arash Safari Sabet; Bita Shahrami; Ghazaleh Kheiri; Kobra Bagheri Valami; Maryam Barkhordar; Neda Alijani; Negar Nejati; Sahar Tavakoli
|